Principal Biostatistician — Phase I-III Trials Lead

ThermoFisher Scientific; Brussel Hoofdstad; On-site; EUR 70,000 - 120,000; Full time

Job summary

Thermo Fisher Scientific is seeking a Principal Scientist in Biostatistics to lead statistical tasks across the full clinical trial process. You'll design studies, write protocols, and partner with clients in a fast-paced FSP environment to advance transformative therapies.

Expert SAS skills, ICH-GCP knowledge, and successful collaboration with regulatory authorities are essential for ensuring rigorous analyses and high-quality reporting across Phase I–III studies.

Qualifications

• Advanced degree plus 6 years of biostatistics experience in clinical research (Phase I-III).
• Bachelor's degree plus 8 years of biostatistics experience in clinical research.
• Experience with SAS programming and statistical methodology.
• Excellent knowledge of ICH-GCP guidelines and regulatory requirements.
• Ability to develop and review statistical analysis plans.
• Strong project management and multitasking abilities.

Responsibilities

• Lead diverse statistical tasks across the full clinical trial process.
• Collaborate with clients in a Functional Service Provider environment.
• Design studies, write protocols, and contribute to final analyses and reporting.
• Support regulatory interactions and ensure high data quality.

Skills

SAS programming

Statistical methodologies

Analytical problem solving

Written & verbal communication

Regulatory interactions (FDA/EMA)

Team collaboration

Clinical trial analysis experience

Education

Advanced degree in Statistics/Biostatistics

Bachelor's degree in Statistics/Biostatistics

Tools

SAS

R

EAST

WinBUGS

CDISC standards

Job description

Thermo Fisher Scientific is seeking a Principal Scientist in Biostatistics to lead statistical tasks across the full clinical trial process. You'll design studies, write protocols, and partner with clients in a fast-paced FSP environment to advance transformative therapies.

Expert SAS skills, ICH-GCP knowledge, and successful collaboration with regulatory authorities are essential for ensuring rigorous analyses and high-quality reporting across Phase I–III studies.